{
  "docId": "019de075-12bd-74a7-bc75-4587e4948a57",
  "docSlug": "9c54f748d4238e6a3a690a4101a45e99",
  "documentTitle": "Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 50,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "key_messages",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The chart illustrates the correlation between Cyno and Human half-life, showing YTE mAbs (Spyre's approach) outperforming WT mAbs.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de075-12bd-74a7-bc75-4587e4948a57/9",
  "deckHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57",
  "deckJsonHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57.json",
  "deckAnchorHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.35,
        "x": 0.64,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Clinical Precedent: Human Half-Life vs Cyno Half-Life",
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "441e2393-0f85-41c8-a74e-4520c499e5c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.17,
        "y": 0.35
      },
      "kind": "image",
      "text": "Antibody structure diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3844e58f-91f6-4732-a80f-8cf789b69e05",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.42,
        "y": 0.36
      },
      "kind": "list",
      "text": "Potential for IP into 2040s: Novel dosing profile, Improved manufacturability, Coverage of diverse back-up series",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f1b21e4-c657-4454-ad11-5719868c43b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.02,
        "y": 0.65
      },
      "kind": "list",
      "text": "High concentration SQ: Ability to formulate at >150 mg/mL with low viscosity, Citrate-free formulation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cacb9b50-d66a-41d6-9727-4bd75cb02e11",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.18,
        "x": 0.02,
        "y": 0.31
      },
      "kind": "list",
      "text": "Epitopes maintained: Validated pharmacology, Equivalent or better potency",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cbe4affd-82e5-4611-b51c-0182a38349d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.42,
        "y": 0.59
      },
      "kind": "list",
      "text": "Significantly extended half-life: Q8-Q12W dosing based on validated half-life extension technology",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dcccc468-7733-47f0-abc9-81cb0fd97bce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.2,
        "y": 0.21
      },
      "kind": "title",
      "text": "Spyre mAbs introduce significant improvements over 1st generation mAbs",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c7dab6d-2ff3-4d57-9dc1-1e44b0888814",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Spyre mAbs exploit validated biology with modifications designed for best-in-class properties",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64ae143c-45c6-4266-bb1c-9987f8358fa2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "evidence-matrix",
      "slug": null,
      "matchId": "a08ab5ed-98ac-46b7-89ce-fd646627a310",
      "evidence": "Comparison of 1st gen vs Spyre mAbs using clinical data",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 12,
      "from": 9,
      "beatId": "7c8ec290-25a9-4de4-a40c-92ef8949c4a2",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "Slides 9-12 present Spyre's strategy and pipeline.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 12,
      "from": 9,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "0317e287-091e-44c2-9f1e-4137f5bb7b9e",
      "evidence": "Slides 9-12 present Spyre's strategy and pipeline, answering the question of how to address unmet needs in IBD.",
      "position": 0,
      "objective": "What problem does Spyre aim to solve and how?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}